Skip to main content
25 search results for:

Tremelimumab 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 17-11-2022 | FDA | News | Article
    approvalsWatch

    FDA approves durvalumab, tremelimumab, chemo triplet for metastatic NSCLC

    medwireNews : The US FDA has authorized  the use of durvalumab plus tremelimumab alongside first-line platinum-based chemotherapy in the metastatic non-small-cell lung cancer (NSCLC) setting.

  2. 26-01-2022 | Non-small-cell lung cancer | News | Article

    Radiotherapy futile add-on to durvalumab–tremelimumab in refractory NSCLC

    Adding low-dose or hypofractionated radiotherapy to durvalumab plus tremelimumab offers no significant benefit to people with non-small-cell lung cancer that is resistant to PD-1 or PD-L1 inhibition, US study findings indicate.

  3. 09-09-2021 | WCLC 2021 | Conference coverage | Article

    Durvalumab–tremelimumab plus chemo ‘a potential new first-line option’ for metastatic NSCLC

    The addition of durvalumab plus tremelimumab to chemotherapy significantly improves the outcomes of people with untreated metastatic non-small-cell lung cancer, shows the POSEIDON trial.

  4. 20-04-2021 | Mesothelioma | News | Article

    Retreatment with tremelimumab–durvalumab feasible in mesothelioma patients

    The NIBIT-MESO-1 trial suggests that retreatment with tremelimumab plus durvalumab could be a viable option for patients with unresectable mesothelioma who progress after initially benefiting from the combination.

  5. 08-10-2020 | ESMO 2020 | Conference coverage | Article

    Durvalumab, alone or with tremelimumab, fails to boost metastatic UC survival

    The DANUBE trial has ruled out the first-line use of durvalumab monotherapy or alongside tremelimumab in patients with metastatic urothelial carcinoma after failing to show an overall survival advantage for either option relative to standard of care chemotherapy.

  6. 24-05-2018 | Mesothelioma | News | Article

    Tremelimumab plus durvalumab active in unresectable mesothelioma

    Preliminary results suggest a role for the combination of the CTLA-4 inhibitor tremelimumab and the PD-L1 blocker durvalumab in the treatment of inoperable pleural or peritoneal mesothelioma.

  7. 06-08-2021 | Urothelial cancer | Feature | Article
    Updated January 2023

    At a glance: First-line immunotherapy for advanced urothelial carcinoma

    Related news content: PFS boost with atezolizumab–chemotherapy in advanced urothelial carcinoma   Researcher comment: IMvigor130 trial of atezolizumab in advanced urothelial cancer (video) IMvigor130 PROs add support for atezolizumab–chemotherapy use in advanced UC   Single-agent atezolizumab supported for some cisplatin-ineligible mUC patients (video) Single-agent atezolizumab supported for some cisplatin-ineligible mUC patients (video) DANUBE Phase 3 Patient population: Treatment-naïve patients with locally advanced or metastatic urothelial cancer Treatments: Durvalumab 1500 mg every 4 weeks; four doses of durvalumab 1500 mg plus tremelimumab 75 mg every 4 weeks, followed by durvalumab monotherapy; or six cycles of gemcitabine plus cisplatin or carboplatin https://clinicaltrials.gov/ct2/show/NCT02516241 Sponsor: AstraZeneca This trial did not meet either of its co-primary endpoints, showing no significant OS boost with durvalumab versus chemotherapy in the PD-L1-high population (median, 14.4 vs 12.1 months), nor with durvalumab plus tremelimumab versus chemotherapy in the intention-to-treat population (median, 15.1 vs 12.1 months).

  8. 22-10-2020 | Urothelial cancer | News | Article

    Neoadjuvant dual immune-checkpoint blockade shows promise in UC

    The first study, by Jianjun Gao and colleagues from The University of Texas MD Anderson Cancer Center in Houston, USA, included 28 patients (median age 71 years, 71% men) who were treated with two cycles of the PD-L1 inhibitor durvalumab 1500 mg/kg and the CTLA-4 inhibitor tremelimumab 75 mg/kg every 4 weeks before cystectomy.

  9. 14-10-2020 | Immunotherapy | News | Article

    Prior immune-related AEs linked to high radiation pneumonitis risk

    Their study included data for 496 consecutive patients treated with atezolizumab, nivolumab, ipilimumab, pembrolizumab, durvalumab, or tremelimumab between 2014 and 2020.

  10. 25-09-2020 | ESMO 2020 | Conference coverage | Article

    Long-term ES-SCLC outcomes on durvalumab–chemotherapy predicted by PFS duration

    In total, 17.0% of 265 patients in the CASPIAN trial taking durvalumab plus platinum–etoposide had PFS lasting 12 months or more, as did 16.4% of the 531 patients combining those who took durvalumab and chemotherapy with or without tremelimumab, as well as 4.5% of the 266 who received only chemotherapy.

  11. 08-01-2019 | Immunotherapy | News | Article

    No difference in efficacy of cancer immunotherapy by sex

    But the authors point out that the current study expanded the search criteria to include trials of atezolizumab, durvalumab, and avelumab, in addition to those testing ipilimumab, tremelimumab, nivolumab, and pembrolizumab.

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.